Tag Archives: BioMarin

May, 2018

November, 2017

October, 2017

April, 2017

March, 2016

January, 2016

  • 14 January

    FDA Rejects Biomarin’s Duchenne Muscular Dystrophy Drug

    SAN RAFAEL, Calif., Jan. 14, 2016 (GLOBE NEWSWIRE) — BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Response letter to the Company’s New Drug Application (NDA) for KyndrisaTM (drisapersen) for the treatment of Duchenne muscular dystrophy (Duchenne) amenable to exon 51 …

November, 2015

  • 25 November

    FDA Panel Says BioMarin DMD Drug Data Not Persuasive

    SAN RAFAEL, Calif., Nov. 24, 2015 (GLOBE NEWSWIRE) — BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that the Peripheral and Central Nervous System Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) met to discuss the data submitted to support the New Drug Application (NDA) for KyndrisaTM (drisapersen) for …